Doxorubicinone is primarily utilized in the field of oncology as a key intermediate in the synthesis of doxorubicin, a potent chemotherapeutic agent. Its role is crucial in the production of this drug, which is widely used to treat various cancers, including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia. The compound's structural framework allows for the effective targeting of cancer cells, leading to the inhibition of DNA and RNA synthesis, thereby preventing the proliferation of malignant cells. Additionally, doxorubicinone's derivatives are explored for their potential in developing new anticancer therapies, offering hope for more effective and targeted treatments with reduced side effects.